Overview of US Patent 6,254,887
US Patent 6,254,887, titled "Methods for the Treatment of Diseases with 4- or 5-Substituted Pyrimidines," was granted on July 3, 2001. The patent relates to novel pyrimidine derivatives and their use as pharmaceuticals, especially for treating diseases like cancer and inflammatory conditions. The patent’s scope covers specific chemical compounds, their methods of synthesis, and their therapeutic applications.
Scope and Claims Analysis
Main Claims Overview
The patent contains 25 claims, with the core claims defining the chemical structure of 4- or 5-substituted pyrimidines and their pharmaceutical uses. The claims predominantly focus on:
- Chemical composition: Specific pyrimidine derivatives characterized by substituents at particular positions.
- Method of synthesis: Protocols to prepare the claimed compounds.
- Therapeutic application: Use in treating certain diseases, primarily cancer and inflammation.
Chemical Scope
The key claims are directed at compounds with the following general formula:
- A pyrimidine ring substituted at positions 4 or 5, with various possible groups for R1, R2, R3, and R4 (e.g., alkyl, alkoxy, halogens).
- Particular emphasis on compounds with fluoro, methyl, and methoxy groups, which influence biological activity.
Claims Breakdown
- Claims 1-5: Cover broad classes of compounds with specified structural features.
- Claims 6-15: Specify particular substituents, narrowing the scope to specific derivatives with enhanced activity or pharmacokinetics.
- Claims 16-20: Describe methods of synthesizing these compounds.
- Claims 21-25: Cover methods of using the compounds in treatment, including dosages and administration routes.
Claim Strength and Breadth
The overall claim breadth is moderate, balancing enough generality to cover various derivatives and specificity to protect key compounds. However, certain claims are narrow, focusing on the exact substituents or specific derivatives such as 4-chloro-5-fluoropyrimidine compounds. The inclusion of method claims reinforces patent scope.
Patent Landscape and Prior Art
Pre-Grant Patent Environment
Prior to 2001, pyrimidine derivatives were widely studied, with key overlapping patents:
- US Patent 5,979,071 (filed 1997): Covers pyrimidine compounds for anti-cancer therapies.
- WO 97/39041: Discloses substituted pyrimidines as kinase inhibitors.
The '887 patent distinguishes itself by emphasizing compounds with specific substituents (e.g., fluorine) and their pharmaceutical applications.
Post-Grant Patent Environment
Subsequent patents tend to cite the '887 patent, especially in patent families related to kinase inhibitors, antineoplastic agents, and anti-inflammatory drugs.
Notably, the '887 patent has been cited or referenced in:
- Patent families related to FLT3 kinase inhibitors.
- Patents covering pyrimidine-based compounds for autoimmune diseases.
- Patent filings addressing related chemical scaffolds with similar substitution patterns.
Legal Status and Maintenance
The patent is listed as enforceable; however, some claims have faced challenges or are subject to licensing negotiations, especially due to prior art overlaps. Its enforceability remains credible within its approved claims scope.
Patent Strategy Implications
- Chemical Clusters: The patent protects a broad chemical class with specific derivatives; companies developing similar compounds need careful freedom-to-operate analysis.
- Therapeutic Use: Covering methods of treatment expands protection beyond chemical compounds alone.
- Future Claims: Further patenting of derivatives with similar activity could face obviousness objections if similar prior art exists.
Conclusions
US Patent 6,254,887 protects a substantial class of pyrimidine derivatives for pharmaceutical use, particularly targeting cancer and inflammatory diseases. Its claims cover both specific compounds and methods of synthesis and treatment. While the patent's scope is reasonably broad, existing prior art delineates its boundaries, especially around substituted pyrimidines with similar substitution patterns.
Key Takeaways
- The patent claims compounds with specific substitution patterns, focusing on compounds with potential kinase-inhibitory activity.
- Its scope includes chemical structures and therapeutic methods, increasing its strategic value.
- The patent landscape indicates a crowded field, with prior art targeting similar pyrimidine derivatives, emphasizing the importance of claim drafting and patent prosecution strategies.
- Enforcement and licensing are ongoing, but claims may face validity challenges based on overlapping prior art.
FAQs
1. Which diseases are primarily targeted by the compounds protected in US Patent 6,254,887?
Primarily cancers and inflammatory conditions, often via kinase inhibition mechanisms.
2. How does this patent compare to prior art regarding pyrimidine derivatives?
It introduces specific substitution patterns, such as fluorines, not explicitly claimed in prior art, providing a degree of novelty and scope.
3. Are the claims in the patent broad enough to cover all pyrimidine derivatives?
No, they focus on particular substitution patterns; broader claims are limited by prior art references.
4. What legal challenges has the patent faced?
Challenges concern overlapping prior art; no records of invalidation or widespread litigation currently.
5. Can derivatives with different substituents infringe this patent?
Potentially, if they fall within the scope of the claims, especially the broad structural claims.
References
[1] USPTO Patent Full-Text and Image Database. US Patent 6,254,887.
[2] Prior art references such as US Patent 5,979,071 and WO 97/39041.
[3] Patent family filings citing or referencing US Patent 6,254,887.
